FDA, EMA Decisions On Avandia Reflect The Power Of REMS

Contrasting decisions by FDA and the European Medicines Agency on the fate of GlaxoSmithKline’s Avandia reflect not so much a divergence of scientific opinion between the two regulators, but rather differences in how they chose to manage the drug’s cardiovascular risks and the tools available for doing so.